Agomab Therapeutics NV, headquartered in Ghent, Belgium, is a clinical-stage biopharmaceutical company dedicated to pioneering treatments for fibro-stenotic and regenerative diseases. Established in 2017, the company leverages its deep understanding of growth factor biology to develop a pipeline of small molecules and antibodies designed to modulate pathways that drive fibrosis and tissue repair. Agomab’s therapeutic strategy focuses on two primary pathways: the Transforming Growth Factor beta (TGF-β) pathway and the Hepatocyte Growth Factor (HGF) pathway. Their lead clinical candidate, AGMB-129, is a gut-restricted, small-molecule inhibitor of ALK5 (TGF-β receptor 1) currently being evaluated for the treatment of fibrostenotic Crohn’s disease. By inhibiting ALK5 locally in the gastrointestinal tract, the company aims to prevent and reverse the fibrotic complications that often lead to surgery in Crohn's patients. In addition to its gastrointestinal programs, Agomab is developing AGMB-447, an inhaled ALK5 inhibitor for Idiopathic Pulmonary Fibrosis (IPF), and AGMB-101, a MET-agonistic antibody designed for regenerative applications in organ failure. The company’s approach combines precision medicinal chemistry with a focus on high unmet medical needs in chronic inflammatory conditions. Led by CEO Tim Knotnerus, Agomab has secured significant backing from prominent life sciences investors and successfully transitioned to a public company on the NASDAQ exchange to fund its expanding clinical trials and research initiatives.
Gross margin measures the amount of revenue that remains after subtracting costs directly associated with production.
The EBITDA margin is a measure of a company's operating profit desconsidering D&A costs as a percentage of its revenue.
The EBIT margin is a measure of a company's operating profit considering D&A costs as a percentage of its revenue.
The net profit margin, or simply net margin, measures how much net income or profit is generated as a percentage of revenue. It is the ratio of net profits to revenues for a company or business segment.
Many companies have a high D&A in relation to the company's operating profit (EBITDA) and although this indicator does not have an effective cash effect, it ends up influencing the accounting net income, so analyzing this relationship can help to understand when D&A has a relevant impact to the company's results.
Shows the amount spent on investments in research and development in relation to the Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
Shows the amount spent on investments in Capex in relation to Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
Indicates a comparison between investments in fixed/intangible assets and the depreciation and amortization of some company assets. It serves to let managers know that the company's assets are devaluing periodically, and whether CAPEX has followed the same pace or not.
It shows the percentage of operating cash flow that the company uses in Capex (investments in fixed and intangible assets). When your result is greater than 100%, it demonstrates that there are expenses greater than what the company produces in its operations.
It demonstrates the percentage cost of Stock-Based Compensation compared to the company's operating cash flow. In some companies, the OCF is positive because of the SBC, which can lead to an incorrect cash flow analysis.
If the company has a lot of D&A, it helps to see if most of it tends to come from fixed assets. The account can include machinery, equipment, vehicles, buildings, land, office equipment, and furnishings, among other things.
If the company has a lot of D&A, it helps to see if most of it tends to come from Goodwill, that is an intangible asset that accounts for the excess purchase price of another company.
Return on equity (ROE) is the measure of a company's net income divided by its shareholders' equity and is a gauge of a corporation's profitability and how efficiently it generates those profits.
Return on invested capital (ROIC) is a calculation used to assess a company's efficiency in allocating capital to profitable investments. The formula for calculating ROIC involves dividing Net Income by the average of invested capital.
...and much more!